Form 4: NovaBay Pharmaceuticals Director Acquires 30,000 Restricted Stock Units

Paul E. Freiman, a director of NovaBay Pharmaceuticals, acquired 30,000 restricted stock units on May 28, 2024, according to a recent SEC Form 4 filing.

Summary

• Paul E. Freiman, a director of NovaBay Pharmaceuticals, acquired 30,000 restricted stock units on May 28, 2024.
• Each restricted stock unit represents a contingent right to receive one share of NovaBay's common stock.
• The restricted stock units vest on the one-year anniversary of the grant date.
• The filing indicates that the reported amount does not reflect the 1-for-35 reverse stock split that took effect on May 30, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting an insider transaction. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or any individuals owning more than 10% of a company's shares) buy or sell the company's securities. These filings provide transparency to the market regarding insider transactions.

Stakeholder Impact

• The acquisition of restricted stock units by a director could be perceived positively by shareholders, as it aligns the director's interests with the company's long-term performance.

Key Dates

Keywords

restricted stock units, Form 4, insider trading, NovaBay Pharmaceuticals, NBY, Paul E. Freiman, director, acquisition